1-Boc-3-hydroxypiperidine CAS 85275-45-2

PI3Kδ Inhibitors: For chronic lymphocytic leukemia treatment, PI3Kδ inhibitors incorporate the (R)-1-Boc-3-hydroxypiperidine moiety. The steric hindrance of the piperidine ring modulates the binding mode between drugs and the PI3Kδ active pocket, thereby enhancing the selective killing of tumor cells.

JAK Inhibitors: Some JAK family inhibitors (e.g., dual JAK1/JAK2 inhibitors) adopt 1-Boc-3-hydroxypiperidine as a key intermediate to construct piperidine-containing heterocyclic linkers.

This structure regulates drug water solubility and cell membrane permeability, and optimizes oral absorption efficiency.

Immune Checkpoint Modulators: Small-molecule PD-L1 inhibitors and CD47 antagonists for tumor immunotherapy undergo coupling reactions between hydroxyl and amino groups of 1-Boc-3-hydroxypiperidine to conjugate immunomodulatory active fragments. This strategy enables the synthesis of bifunctional drug molecules with both targeting and immunoregulatory properties.

1. Antihypertensive and Antiarrhythmic Drugs

β-Blocker Derivatives: In structural optimization of conventional β-blockers (e.g., propranolol, metoprolol), the 1-Boc-3-hydroxypiperidine fragment replaces original aliphatic amine side chains. The rigid piperidine skeleton strengthens hydrophobic binding to β-receptors, while polar hydroxyl groups improve water solubility and reduce central nervous system side effects caused by excessive lipophilicity.Calcium Channel Blockers (CCBs): Novel derivatives of dihydropyridine and phenylalkylamine CCBs utilize (R)-1-Boc-3-hydroxypiperidine as an intermediate to construct chiral piperidinyl side chains.

Stereoregulation of the C3 hydroxyl group precisely blocks calcium channels on vascular smooth muscle cell membranes, delivering milder and long-lasting hypotensive effects and mitigating adverse reactions such as lower limb edema and tachycardia.

Potassium Channel Modulators: Selective IKr inhibitors for ventricular arrhythmia are synthesized based on the key chiral fragment derived from (S)-1-Boc-3-hydroxypiperidine. Esterification modification of hydroxyl groups adjusts the lipophilic-hydrophilic partition coefficient and prolongs the drug action duration in cardiomyocytes.

2. Drugs for Diabetes and Metabolic Disorders

DPP-4 Inhibitors: Dipeptidyl peptidase 4 (DPP-4) is a vital therapeutic target for type 2 diabetes. Multiple novel DPP-4 inhibitors take 1-Boc-3-hydroxypiperidine as the core building block. After Boc deprotection, the exposed amino group conjugates with heterocycles such as triazole and pyrimidine to form highly selective DPP-4 binding sites. These agents suppress enzymatic activity, prevent degradation of endogenous incretins including GLP-1 and GIP, and achieve stable hypoglycemic effects with no hypoglycemia risk.

SGLT2 Inhibitor Derivatives: In structural modification of sodium-glucose cotransporter 2 (SGLT2) inhibitors, the piperidine moiety of 1-Boc-3-hydroxypiperidine is introduced.Etherification between hydroxyl groups and glucose fragments enhances specific SGLT2 inhibition, optimizes renal drug distribution, and synergistically boosts hypoglycemic and diuretic efficacy.

Lipid-Regulating Drugs: Dual PPARα/γ agonists for triglyceride and cholesterol reduction employ 1-Boc-3-hydroxypiperidine as a linking unit to couple fatty acid side chains and heterocyclic active groups. It modulates agonistic activity against peroxisome proliferator-activated receptors and realizes comprehensive blood lipid regulation.

1. Anti-Infective Pharmaceuticals

Antibacterial Agents: Novel oxazolidinone and quinolone antibiotics targeting drug-resistant Gram-positive bacteria (e.g., MRSA, VRE) use 1-Boc-3-hydroxypiperidine as an intermediate to incorporate chiral piperidine rings. Acylation modification of hydroxyl groups enhances inhibitory activity against bacterial cell wall synthetase and DNA gyrase, while lowering cytotoxicity to human cells.Antiviral Drugs: Small-molecule inhibitors against HIV and hepatitis C virus (HCV) leverage the dual functional amino and hydroxyl groups of 1-Boc-3-hydroxypiperidine to construct binding pockets for viral proteases (e.g., HIV protease, HCV NS3/4A protease).

Steric hindrance and hydrogen bonding interactions block viral replication. Piperidinyl derivatives of some anti-influenza drugs are also synthesized via this intermediate.

Antifungal Agents: New azole antifungal drugs (e.g., fluconazole derivatives) replace traditional imidazole side chains with (R)-1-Boc-3-hydroxypiperidine. This modification improves selective inhibition on fungal cytochrome P450 14α-demethylase, strengthens activity against Candida and Cryptococcus, and reduces drug interactions induced by hepatic drug enzyme inhibition.

2. Neurological Disease Drugs

Anti-Alzheimer's Drugs: Emerging therapeutics targeting acetylcholinesterase (AChE) and β-amyloid aggregation adopt 1-Boc-3-hydroxypiperidine as a core scaffold to design bifunctional molecules with cholinergic agonism and anti-amyloid deposition effects. The piperidine amino group binds to AChE active sites, whereas hydroxyl groups inhibit β-amyloid fibrillation.Antidepressant and Anxiolytic Drugs: Structural optimization of dual 5-HT/NE reuptake inhibitors introduces the (S)-1-Boc-3-hydroxypiperidine fragment to regulate affinity for monoamine neurotransmitter transporters.

It extends the residence time of neurotransmitters in synaptic clefts and improves drug onset speed and tolerability.

Antiepileptic Drugs: Novel antiepileptics connect active moieties such as barbituric acid and benzodiazepine via hydroxyl and amino groups of 1-Boc-3-hydroxypiperidine, developing multi-target agents acting on GABA receptors and sodium channels. These compounds enhance anticonvulsant potency and alleviate central side effects including drowsiness and dizziness.

With the advancement of fine chemicals and biotechnology, the applications of 1-Boc-3-hydroxypiperidine have transcended traditional pharmaceutical synthesis, expanding into functional materials, bioconjugation, molecular probes and other emerging sectors:

Functional Polymer Materials: Used as a monomer, 1-Boc-3-hydroxypiperidine undergoes polycondensation with diisocyanates and dicarboxylic acids to synthesize piperidine-containing polyamides, polyurethanes and polyesters.

The alkalinity and rigidity of the piperidine ring enhance mechanical strength, heat resistance and antistatic properties, supporting applications in high-end coatings and medical polymer materials.

Biomolecular Crosslinkers: 3-hydroxypiperidine obtained after Boc deprotection serves as a conjugation bridge for biomolecules (proteins, antibodies, nucleic acids). Its amino groups bind to carboxyl groups of biomolecules, and hydroxyl groups conjugate with fluorescent dyes and targeted ligands, enabling the preparation of fluorescent-labeled antibodies and antibody-drug conjugates (ADCs) for bioimaging and targeted therapy.

Molecular Probes and Sensors: Based on the 1-Boc-3-hydroxypiperidine skeleton, fluorescent groups (coumarin, rhodamine) and recognition groups (crown ether, boric acid) are conjugated to develop fluorescent probes for metal ions (Zn²⁺, Cu²⁺) and small biomolecules (glucose, amino acids). The favorable water solubility and selective binding capacity of the piperidine ring allow real-time in vivo detection of target molecules.

Agrochemicals: It is applied in the synthesis of novel plant growth regulators and pesticides. The piperidine structure mimics plant hormones to regulate plant growth and development, or acts on insect nervous systems to deliver high-efficiency and low-toxicity insecticidal effects.